General company profile

Alnylam is leading the development of RNA interference (RNAi) into an entirely new class of innovative drugs that can transform the lives of patients with limited or inadequate treatment options. Founded in 2002, Alnylam was founded on a bold vision to turn a scientific discovery into reality, now featuring a robust development platform and a broad pipeline of investigational drugs, with 4 registered drugs to date.
Alnylam has an international office in Amsterdam, where more than 50 employees ensure that our medicines reach patients all over the world.

Company info


Create a job alert

Would you like to receive the latest vacancies in your e-mail box? Create a job alert based on your keyword(s) and preferences.

Sign up

Hyphen Projects uses cookies to remember certain preferences and align interests.
By continuing to use this site, you consent to our use of cookies.